Active Ingredient History
Alagebrium was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic heart failure. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aging (Phase 2/Phase 3)
Cardiovascular Diseases (Phase 2/Phase 3)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetic Nephropathies (Phase 2)
Dyspnea (Phase 2)
Endothelial Cells (Phase 2/Phase 3)
Exercise (Phase 2/Phase 3)
Heart Failure (Phase 2)
Heart Failure, Diastolic (Phase 2)
Hypertension (Phase 2)
Hypertrophy, Left Ventricular (Phase 2)
Pulmonary Edema (Phase 2)
Ventricular Function (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue